US & Canada regulatory framework – organization of FDA MCQs With Answer

Introduction:

The US and Canadian regulatory frameworks are essential knowledge for M.Pharm students preparing to work in drug development, regulatory affairs, or quality assurance. This set of MCQs focuses on the organization and responsibilities of the US Food and Drug Administration (FDA) and the parallel regulatory bodies in Canada, highlighting key legislations, application types (IND, NDA, ANDA, BLA, 505(b)(2)), inspection practices, and post-market systems. Questions emphasize practical regulatory decision points, centers and directorates, submission pathways, and compliance mechanisms used in both jurisdictions. These targeted MCQs will deepen understanding of regulatory strategy and inspection expectations for pharmaceutical products in North America.

Q1. Which law provides the FDA with its principal authority to regulate foods, drugs, and cosmetics in the United States?

• Public Health Service Act
• Federal Food, Drug, and Cosmetic Act
• Biologics Control Act
• Drug Price Competition and Patent Term Restoration Act

Correct Answer: Federal Food, Drug, and Cosmetic Act

Q2. Which FDA center is primarily responsible for the regulation of most therapeutically active small-molecule drugs?

• Center for Biologics Evaluation and Research (CBER)
• Center for Devices and Radiological Health (CDRH)
• Center for Drug Evaluation and Research (CDER)
• Center for Tobacco Products (CTP)

Correct Answer: Center for Drug Evaluation and Research (CDER)

Q3. What regulatory submission must a sponsor file with the FDA to begin clinical trials of an investigational drug in humans?

• New Drug Application (NDA)
• Abbreviated New Drug Application (ANDA)
• Investigational New Drug Application (IND)
• Biologics License Application (BLA)

Correct Answer: Investigational New Drug Application (IND)

Q4. Which application pathway is used for generic drugs that demonstrate bioequivalence to a reference listed drug?

• 505(b)(2) Application
• New Drug Submission (NDS)
• Abbreviated New Drug Application (ANDA)
• Biologics License Application (BLA)

Correct Answer: Abbreviated New Drug Application (ANDA)

Q5. The Prescription Drug User Fee Act (PDUFA) is primarily intended to do which of the following?

• Create new clinical trial requirements for sponsors
• Authorize user fees to fund and accelerate FDA drug review
• Replace the Federal Food, Drug, and Cosmetic Act
• Mandate product recalls

Correct Answer: Authorize user fees to fund and accelerate FDA drug review

Q6. Which Code of Federal Regulations parts contain the FDA’s current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals?

• 21 CFR Parts 50 and 56
• 21 CFR Parts 210 and 211
• 21 CFR Parts 600 and 610
• 21 CFR Part 11 only

Correct Answer: 21 CFR Parts 210 and 211

Q7. What is the purpose of an FDA Form 483 issued to a manufacturing facility after inspection?

• To serve as a final warning of license revocation
• To document voluntary recalls required by FDA
• To report inspectional observations of potential regulatory significance
• To provide pre-approval review comments on an NDA

Correct Answer: To report inspectional observations of potential regulatory significance

Q8. In Canada, which submission is the formal application to obtain market authorization for a new pharmaceutical product?

• New Drug Application (NDA)
• Notice of Compliance (NOC)
• New Drug Submission (NDS)
• Drug Identification Number (DIN) Application

Correct Answer: New Drug Submission (NDS)

Q9. Which directorate within Health Canada is primarily responsible for regulating biologic and biotechnology-derived health products?

• Therapeutic Products Directorate (TPD)
• Biologics and Genetic Therapies Directorate (BGTD)
• Marketed Health Products Directorate (MHPD)
• Natural and Non-prescription Health Products Directorate (NNHPD)

Correct Answer: Biologics and Genetic Therapies Directorate (BGTD)

Q10. What is the Drug Identification Number (DIN) used for in the Canadian regulatory system?

• To identify clinical trial sponsors
• To uniquely identify a marketed drug product authorized for sale in Canada
• To track adverse events reported to Health Canada
• To classify drugs under the Patent Act

Correct Answer: To uniquely identify a marketed drug product authorized for sale in Canada

Q11. For approval of an ANDA, the applicant must demonstrate which primary scientific criterion?

• New clinical efficacy trials
• Bioequivalence to the reference listed drug
• Novel mechanism of action
• Manufacturing process patent ownership

Correct Answer: Bioequivalence to the reference listed drug

Q12. Biologics License Applications (BLAs) are regulated in part under which US statute?

• Federal Food, Drug, and Cosmetic Act only
• Public Health Service Act
• Controlled Substances Act
• Biologics Exclusivity Act

Correct Answer: Public Health Service Act

Q13. FAERS is the FDA database used primarily to monitor what type of post-market information?

• Manufacturing inspection schedules
• Adverse event reports and medication error reports for drugs and biologics
• Laboratory method validation reports
• Drug pricing and reimbursement data

Correct Answer: Adverse event reports and medication error reports for drugs and biologics

Q14. Under US orphan drug regulations, a disease or condition generally qualifies for orphan designation when it affects fewer than how many people in the United States?

• 50,000
• 200,000
• 1,000,000
• 2,000

Correct Answer: 200,000

Q15. Which FDA office is primarily responsible for conducting domestic and foreign inspections and enforcement activities?

• Office of New Drugs (OND)
• Office of Regulatory Affairs (ORA)
• Center for Drug Evaluation and Research (CDER)
• Office of Chief Counsel

Correct Answer: Office of Regulatory Affairs (ORA)

Q16. In Canada, the issuance of a Notice of Compliance (NOC) signifies which regulatory outcome?

• Conditional clinical trial authorization
• Refusal of the New Drug Submission
• Authorization to market the drug in Canada
• Assignment of a Drug Identification Number (DIN) only

Correct Answer: Authorization to market the drug in Canada

Q17. Are recommendations made by FDA advisory committees legally binding on the agency’s final approval decisions?

• Yes — FDA must follow committee votes
• No — advisory committee advice is non-binding and advisory
• Only for biologics, they are binding
• Only when there is unanimous vote

Correct Answer: No — advisory committee advice is non-binding and advisory

Q18. What is the primary purpose of a Drug Master File (DMF) submitted to the FDA?

• To request orphan drug exclusivity
• To confidentially provide detailed chemistry, manufacturing or quality information to support another party’s regulatory submission
• To register a clinical investigator
• To serve as an NDA-equivalent drug application in Canada

Correct Answer: To confidentially provide detailed chemistry, manufacturing or quality information to support another party’s regulatory submission

Q19. Which regulatory pathway allows a sponsor to obtain approval relying in part on published literature or FDA findings for a previously approved drug?

• ANDA pathway
• 505(b)(2) application
• Biologics License Application (BLA)
• Investigational New Drug (IND)

Correct Answer: 505(b)(2) application

Q20. Which Health Canada directorate is primarily responsible for post-market safety monitoring and activities for marketed health products?

• Therapeutic Products Directorate (TPD)
• Marketed Health Products Directorate (MHPD)
• Biologics and Genetic Therapies Directorate (BGTD)
• Health Products and Food Branch Inspectorate (HPFBI)

Correct Answer: Marketed Health Products Directorate (MHPD)

Download